PYXS

Company Announcement: Pyxis Oncology, Inc. will have its CEO, Dr. Lara S. Sullivan, participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on April 9, 2025, and will also conduct one-on-one investor meetings during the event.

Product Development Focus: The company is advancing its lead product candidate, MICVO, an antibody-drug conjugate targeting difficult-to-treat cancers, particularly focusing on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Preclinical Data Presentation: Pyxis Oncology is set to present promising preclinical data on micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting EDB+FN, at the AACR Annual Meeting, highlighting its potential efficacy in treating recurrent and metastatic head and neck squamous cell carcinoma.

Clinical Trials Advancement: The company is advancing MICVO into clinical trials as both a monotherapy and in combination with Merck's Keytruda, with preliminary data expected in late 2025 and early 2026, following positive results from earlier studies indicating significant tumor regression.

Analyst Ratings: RBC Capital's Leonid Timashev maintains a Buy rating on Pyxis Oncology with a price target of $8.00, while LifeSci Capital also issued a Buy rating; however, William Blair reiterated a Hold rating.

Stock Performance: Pyxis Oncology's shares closed at $1.07, with a one-year high of $6.18 and a low of $0.99, indicating significant volatility in its stock performance.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Company Announcement: Pyxis Oncology, Inc. will have its CEO, Dr. Lara S. Sullivan, participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2025, with a live webcast available on their website.

About Pyxis Oncology: The company is focused on developing next-generation therapeutics for challenging cancers, specifically highlighting their antibody-drug conjugate PYX-201, which targets tumor microenvironments and is currently in Phase 1 clinical studies.

FDA Fast Track Designation: Pyxis Oncology's PYX-201 has received Fast Track Designation from the FDA for treating recurrent or metastatic head and neck squamous cell carcinoma, highlighting its potential to meet significant medical needs in this area.

Ongoing Clinical Trials: Two clinical trials for PYX-201 are currently recruiting participants, one evaluating it as a monotherapy and the other assessing its combination with Merck's KEYTRUDA in advanced solid tumors.

FDA Fast Track Designation: Pyxis Oncology's lead candidate, PYX-201, received Fast Track Designation from the U.S. FDA for treating recurrent or metastatic head and neck squamous cell carcinoma after prior therapies.

Clinical Trials: PYX-201 is currently being tested in two clinical trials, focusing on its effectiveness as a standalone treatment and in combination with Merck’s Keytruda, with both trials actively enrolling patients.

Cash Burn and Runway: Pyxis Oncology has a cash reserve of US$145 million with a cash burn rate of US$54 million per year, providing it with a cash runway of approximately 2.7 years, which is considered prudent despite the company generating only US$16 million in revenue last year.

Investment Risks: The company's cash burn represents about 71% of its market capitalization of US$76 million, indicating a high risk of dilution for shareholders if additional funds are needed, although recent reductions in cash burn suggest some operational sustainability.

Clinical Trials Initiation: Pyxis Oncology has launched Phase 1/2 trials for its antibody-drug conjugate PYX-201, targeting Extradomain-B Fibronectin (EDB+FN) in combination with Merck's KEYTRUDA® for various solid tumors, including recurrent/metastatic head and neck squamous cell carcinoma.

Commitment to Innovation: The company is dedicated to developing innovative cancer therapies, aiming to provide treatment options for patients with limited alternatives, as evidenced by the expansion of ongoing monotherapy trials for PYX-201.

Portfolio Prioritization: Pyxis Oncology has decided to deprioritize its second clinical program, PYX-106, to focus resources on advancing its lead program, PYX-201, which has shown promising preliminary results in treating various solid tumors.

Future Plans and Financial Outlook: The company plans to conduct further studies on PYX-201, with preliminary data expected in 2025-2026, while its current cash position is sufficient to fund these trials into the second half of 2026.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

U.S. Stock Market Performance: U.S. stocks saw gains with the Dow Jones increasing by over 500 points, while energy shares rose by 1.6%. Notable movements included Quantum Computing Inc. surging 29% and Snowflake Inc. jumping 32% after strong earnings reports.

Global Market Trends: European shares closed higher, but Asian markets mostly declined. In economic news, U.S. existing home sales rose by 3.5%, while initial jobless claims decreased by 6,000, indicating mixed economic signals.

U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones rising over 400 points while the NASDAQ fell slightly. Notable movements included significant gains for Quantum Computing Inc. and Snowflake Inc., while Cool Company Ltd. and Pyxis Oncology saw substantial declines.

Economic Indicators: U.S. existing home sales increased by 3.5%, but the Philadelphia Fed Manufacturing Index dropped significantly. Additionally, initial jobless claims decreased, indicating some positive trends in the labor market despite mixed economic signals.

U.S. Stock Market Performance: U.S. stocks saw gains with the Dow Jones up over 100 points, while NVIDIA reported strong earnings, leading to significant increases in shares for Quantum Computing Inc. and Snowflake Inc., among others.

Global Economic Indicators: European shares were mostly higher despite a drop in consumer confidence, while Asian markets closed lower; additionally, U.S. existing home sales rose, but manufacturing indices showed declines.

Preliminary Clinical Data: Pyxis Oncology reported a 50% objective response rate in Head and Neck Squamous Cell Carcinoma patients treated with PYX-201, alongside plans for further studies in combination with Merck's Keytruda and other cancers, with data expected between late 2025 and early 2026.

Market Reaction and Analyst Downgrade: Following the results, William Blair analysts downgraded Pyxis to Market Perform, citing limited effectiveness of PYX-201 outside head-and-neck cancer and reduced the probability of its success from 35% to 10%, leading to a significant drop in stock price.

Stock Movements After Earnings: Snowflake (SNOW) surged 20.2% following strong earnings, with other software companies like MongoDB and Elastic also seeing gains; meanwhile, Copa Holdings and Maximus experienced declines after their earnings reports.

Significant Declines in Other Stocks: Pyxis Oncology plummeted 39.3% due to disappointing data, while Kura Oncology and Backblaze also faced notable drops after strategic collaborations and equity offerings, respectively.

Investor Event Announcement: Pyxis Oncology will host an in-person and virtual investor event on November 20, 2024, to discuss preliminary data from its Phase 1 clinical trial of PYX-201, targeting solid tumors.

Overview of PYX-201: PYX-201 is an antibody-drug conjugate designed to target Extradomain-B Fibronectin within tumors, currently being evaluated for safety and efficacy in patients with relapsed or refractory solid tumors.

Analyst Coverage and Price Forecast: Stephens & Co. has initiated coverage of Pyxis Oncology with an Overweight recommendation, projecting a 112.02% upside in its stock price, with an average target of $9.35/share based on recent data.

Institutional Ownership Trends: There has been a significant increase in institutional ownership of Pyxis Oncology, with 149 funds reporting positions, reflecting a 41.90% rise in the last quarter, while some firms have adjusted their holdings, indicating a generally bullish sentiment towards the company.

Analyst Coverage Initiation: Stephens has begun coverage on Pyxis Oncology Inc, emphasizing its innovative antibody-drug conjugate (ADC) technology and setting an Overweight rating with a price target of $13. The lead drug, PYX-201, targets specific tumor components and is expected to show promising results in upcoming clinical trials.

Financial Position and Market Potential: As of June 30, 2024, Pyxis Oncology reported $157.2 million in cash and equivalents, sufficient to support operations until the second half of 2026. The company's ADC technology is gaining confidence due to recent successes, which could positively influence stock performance.